Xilio Therapeutics Grants Inducement Shares Under Nasdaq Rule

Biotech firm awards stock options to two new employees as part of hiring incentive program.

Apr. 3, 2026 at 8:46pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished metal syringe, a glass vial, and a stethoscope arranged elegantly on a clean, white seamless background, conceptually representing the precision and innovation of Xilio's cancer therapies.Xilio Therapeutics' focus on developing innovative cancer treatments is reflected in the clean, minimalist design of its new employee inducement grants.Waltham Today

Xilio Therapeutics, a clinical-stage biotech company, announced that it has granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under the company's 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.48 per share, which is equal to the closing price of the company's stock on the grant date of April 1, 2026. The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments.

Why it matters

Xilio Therapeutics is leveraging its proprietary masking technology to advance a pipeline of novel, masked immuno-oncology therapies aimed at improving outcomes for cancer patients. The inducement grants are part of the company's efforts to attract and retain top talent as it continues to grow and develop its drug candidates.

The details

The stock options granted to the two new employees are subject to the terms and conditions of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The options have a ten-year term and will vest over a four-year period, with 25% of the shares vesting on the first anniversary of the employee's start date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service with the company.

  • Xilio Therapeutics granted the stock options effective April 1, 2026.

The players

Xilio Therapeutics, Inc.

A clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer.

Got photos? Submit your photos here. ›

The takeaway

The inducement grants from Xilio Therapeutics highlight the company's commitment to building a talented team as it advances its pipeline of novel cancer therapies. The options align the interests of new hires with those of the company and its shareholders as Xilio works to improve outcomes for people living with cancer.